Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Our preclinical studies in animal models have demonstrated promising results in reducing obesity and fatty liver disease.

In addition to a continued focus on growing drug pipelines, and the increasing use of artificial intelligence (AI) and data ...

Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that reduce costs and accelerate production.

Shore Capital, which covers hVIVO, sees plenty of upside. The broker notes that the company’s cash generation, revenue ...

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's rapid-growth life sciences division. Previously, Guillen served as a Board ...

The Acting Chief Executive Officer of the National Vaccine Institute (NVI), Dr. Sodzi Sodzi-Tettey, has reaffirmed his ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

Variations in regulatory requirements across regions often create inefficiencies in drug development—for ... to stay ahead in the fast-paced pharmaceutical industry. DSI provides regulatory ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Serving the pharmaceutical, bioscience and healthcare industry, IAG Cargo’s Constant Climate product is a cutting-edge cold chain solution designed ...